Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MDRNA has announced that the European Patent Office intends to grant a patent for application EP06826368, covering formulations for the intranasal delivery of rapid acting insulin, and its use for the treatment of diabetes.
Subscribe to our email newsletter
Michael French, president and CEO of MDRNA, said: “While our focus remains the development of RNAi-based therapeutics, we believe that the intranasal assets from our predecessor company, Nastech Pharmaceuticals, have considerable value. Specifically, we believe that our insulin intellectual property assets, with the positive results from the Phase II clinical trial completed in 2008, have out-licensing potential.”
The proprietary intranasal insulin formulation covered by EP06826368 provides for a rapid-acting therapy using non-modified forms of insulin. Phase II clinical studies have demonstrated that the intranasal insulin formulation was superior to oral anti-diabetic medications and non-inferior to injectable insulin for control of blood glucose immediately (60 and 90-minutes) after a meal.
The company said that intranasal insulin provided a reduction in hypoglycemia at four hours after a meal, as compared to injectable insulin. These attributes are expected to provide for improved glycemic control. The nasal delivery device used in the trials is compact and easily stored for patient convenience.